Adding radiotherapy to chemotherapy may dramatically improve survival for advanced-stage NSCLC patients

Combining radiotherapy with chemotherapy for patients with limited metastatic non-small cell lung cancer (NSCLC) may curb disease progression dramatically when compared to NSCLC patients who only receive chemotherapy, according to a new randomised phase II clinical trial reported today at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
Markets Insider

Long-term survival rates more than double previous estimates for locally advanced lung cancer

Long-term results of a phase III clinical trial indicate that survival rates for patients receiving chemo-radiotherapy for un-resectable, locally advanced non-small cell lung cancer may be more than twice as high as previous estimates. Findings will be presented at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego.
PRNewswire